These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 23570407)

  • 1. Relevance of molecular characterization of circulating tumor cells in breast cancer in the era of targeted therapies.
    Nadal R; Lorente JA; Rosell R; Serrano MJ
    Expert Rev Mol Diagn; 2013 Apr; 13(3):295-307. PubMed ID: 23570407
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Topoisomerase II alpha expression and the Ki-67 labeling index correlate with prognostic factors in estrogen receptor-positive and human epidermal growth factor type-2-negative breast cancer.
    Tokiniwa H; Horiguchi J; Takata D; Kikuchi M; Rokutanda N; Nagaoka R; Sato A; Odawara H; Tozuka K; Oyama T; Takeyoshi I
    Breast Cancer; 2012 Oct; 19(4):309-14. PubMed ID: 21725655
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic value of circulating tumor cells according to immunohistochemically defined molecular subtypes in advanced breast cancer.
    Munzone E; Botteri E; Sandri MT; Esposito A; Adamoli L; Zorzino L; Sciandivasci A; Cassatella MC; Rotmensz N; Aurilio G; Curigliano G; Goldhirsch A; Nolè F
    Clin Breast Cancer; 2012 Oct; 12(5):340-6. PubMed ID: 23040002
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Towards a personalized breast cancer treatment approach guided by circulating tumor cell (CTC) characteristics.
    Onstenk W; Gratama JW; Foekens JA; Sleijfer S
    Cancer Treat Rev; 2013 Nov; 39(7):691-700. PubMed ID: 23683721
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Biomarkers characterization of circulating tumour cells in breast cancer patients.
    Nadal R; Fernandez A; Sanchez-Rovira P; Salido M; Rodríguez M; García-Puche JL; Macià M; Corominas JM; Delgado-Rodriguez M; Gonzalez L; Albanell J; Fernández M; Solé F; Lorente JA; Serrano MJ
    Breast Cancer Res; 2012 May; 14(3):R71. PubMed ID: 22554015
    [TBL] [Abstract][Full Text] [Related]  

  • 6. HER2-positive circulating tumor cells indicate poor clinical outcome in stage I to III breast cancer patients.
    Wülfing P; Borchard J; Buerger H; Heidl S; Zänker KS; Kiesel L; Brandt B
    Clin Cancer Res; 2006 Mar; 12(6):1715-20. PubMed ID: 16551854
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Changes of HER2 status in circulating tumor cells compared with the primary tumor during treatment for advanced breast cancer.
    Munzone E; Nolé F; Goldhirsch A; Botteri E; Esposito A; Zorzino L; Curigliano G; Minchella I; Adamoli L; Cassatella MC; Casadio C; Sandri MT
    Clin Breast Cancer; 2010 Oct; 10(5):392-7. PubMed ID: 20920984
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The prognostic role of circulating tumor cells (CTCs) detected by RT-PCR in breast cancer: a meta-analysis of published literature.
    Zhao S; Liu Y; Zhang Q; Li H; Zhang M; Ma W; Zhao W; Wang J; Yang M
    Breast Cancer Res Treat; 2011 Dec; 130(3):809-16. PubMed ID: 21311967
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Different prognostic value of cytokeratin-19 mRNA positive circulating tumor cells according to estrogen receptor and HER2 status in early-stage breast cancer.
    Ignatiadis M; Xenidis N; Perraki M; Apostolaki S; Politaki E; Kafousi M; Stathopoulos EN; Stathopoulou A; Lianidou E; Chlouverakis G; Sotiriou C; Georgoulias V; Mavroudis D
    J Clin Oncol; 2007 Nov; 25(33):5194-202. PubMed ID: 17954712
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The prognostic impact of circulating tumor cells in subtypes of metastatic breast cancer.
    Wallwiener M; Hartkopf AD; Baccelli I; Riethdorf S; Schott S; Pantel K; Marmé F; Sohn C; Trumpp A; Rack B; Aktas B; Solomayer EF; Müller V; Janni W; Schneeweiss A; Fehm TN
    Breast Cancer Res Treat; 2013 Jan; 137(2):503-10. PubMed ID: 23271327
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Circulating tumour cells: insights into tumour heterogeneity.
    Hayes DF; Paoletti C
    J Intern Med; 2013 Aug; 274(2):137-43. PubMed ID: 23844916
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Artificial neural network analysis of circulating tumor cells in metastatic breast cancer patients.
    Giordano A; Giuliano M; De Laurentiis M; Eleuteri A; Iorio F; Tagliaferri R; Hortobagyi GN; Pusztai L; De Placido S; Hess K; Cristofanilli M; Reuben JM
    Breast Cancer Res Treat; 2011 Sep; 129(2):451-8. PubMed ID: 21710134
    [TBL] [Abstract][Full Text] [Related]  

  • 13. HER2 status of circulating tumor cells in patients with metastatic breast cancer: a prospective, multicenter trial.
    Fehm T; Müller V; Aktas B; Janni W; Schneeweiss A; Stickeler E; Lattrich C; Löhberg CR; Solomayer E; Rack B; Riethdorf S; Klein C; Schindlbeck C; Brocker K; Kasimir-Bauer S; Wallwiener D; Pantel K
    Breast Cancer Res Treat; 2010 Nov; 124(2):403-12. PubMed ID: 20859679
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Validity of the proliferation markers Ki67, TOP2A, and RacGAP1 in molecular subgroups of breast cancer.
    Milde-Langosch K; Karn T; Müller V; Witzel I; Rody A; Schmidt M; Wirtz RM
    Breast Cancer Res Treat; 2013 Jan; 137(1):57-67. PubMed ID: 23135572
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Detection of occult HER2 mRNA-positive tumor cells in the peripheral blood of patients with operable breast cancer: evaluation of their prognostic relevance.
    Apostolaki S; Perraki M; Kallergi G; Kafousi M; Papadopoulos S; Kotsakis A; Pallis A; Xenidis N; Kalmanti L; Kalbakis K; Agelaki S; Kalykaki A; Stournaras C; Stathopoulos E; Georgoulias V; Mavroudis D
    Breast Cancer Res Treat; 2009 Oct; 117(3):525-34. PubMed ID: 19016323
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Detection of circulating tumor cells in peripheral blood of heavily treated metastatic breast cancer patients.
    Tokudome N; Ito Y; Takahashi S; Kobayashi K; Taira S; Tsutsumi C; Oto M; Oba M; Inoue K; Kuwayama A; Masumura K; Nakayama Y; Watanabe C; Hatake K
    Breast Cancer; 2011 Jul; 18(3):195-202. PubMed ID: 21465230
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Quantitative determination of HER2 expression by confocal microscopy assay in CTCs of breast cancer.
    Cao S; Li Y; Li J; Li CF; Zhang W; Yang ZQ; Meng SD
    Oncol Rep; 2010 Feb; 23(2):423-8. PubMed ID: 20043103
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cytokeratin 19-positive circulating tumor cells in early breast cancer prognosis.
    Saloustros E; Mavroudis D
    Future Oncol; 2010 Feb; 6(2):209-19. PubMed ID: 20146580
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Role of circulating tumor cells and disseminated tumor cells in primary breast cancer.
    Hayashi N; Yamauchi H
    Breast Cancer; 2012 Apr; 19(2):110-7. PubMed ID: 21643809
    [TBL] [Abstract][Full Text] [Related]  

  • 20. mRNA and microRNA expression profiles in circulating tumor cells and primary tumors of metastatic breast cancer patients.
    Sieuwerts AM; Mostert B; Bolt-de Vries J; Peeters D; de Jongh FE; Stouthard JM; Dirix LY; van Dam PA; Van Galen A; de Weerd V; Kraan J; van der Spoel P; Ramírez-Moreno R; van Deurzen CH; Smid M; Yu JX; Jiang J; Wang Y; Gratama JW; Sleijfer S; Foekens JA; Martens JW
    Clin Cancer Res; 2011 Jun; 17(11):3600-18. PubMed ID: 21505063
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.